Total
0
Shares
Tim Oldham appointed as CEO and Managing Director of AdAlta - The Market Herald
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Dr Tim Oldham has been appointed as the CEO and Managing Director of AdAlta
  • He will begin these roles on October 14, 2019
  • Before joining AdAlta, Dr Tim was Executive leader at Tijan Ventures where he provided strategic planning, capital raising, interim executive management and board leadership.
  • AdAlta shares are up 6.67 per cent, trading for 16 cents apiece

AdAlta has appointed global pharmaceutical executive Dr Tim Oldham as Chief Executive Officer and Managing Director effective from October 14, 2019.

Dr Tim has extensive skills over his career in the industry, ranging in strategy and portfolio building, biologic therapies development, and pipeline commercialisation.

He brings more than 20 years' executive leadership experience to AdAlta with his expertise spanning life sciences strategy and business development, commercial and manufacturing operations and alliance management across Europe, Australia and Asia.

"We are delighted to have someone of Tim's calibre and experience join AdAlta as our new Chief Executive Officer," Executive Chairman Paul MacLeman commented.

"Time brings a diverse and international skillset, but his biologics and commercialisation expertise will be invaluable as we approach a number of important milestones," he said.

Before joining AdAlta, Dr Tim was Executive leader at Tijan Ventures where he provided strategic planning, capital raising, interim executive management and board leadership.

Other previous roles have included CEO and Managing Director of Cell Therapies, President of Asia Pacific for Hospira, and a variety of senior management roles with Mayne Pharma.

These roles consisted of the development and commercialisation of pharmaceuticals, devices, biologics and cellular therapies.

Dr Tim was also formerly an engagement manager with global strategy consulting firm McKinsey & Co.

Currently he is Non-Executive Director of transdermal drug delivery company Acrux, and bi-specific antibody company Immunexus. He is also a member of the board of BioMelbourne Network.

AdAlta shares are up 6.67 per cent, trading for 16 cents apiece at 3:45 pm AEST.

1AD by the numbers
More From The Market Herald
Lucas Drilling (ASX:AJL) - CEO, Brett Tredinnick - The Market Herald

" Brett Tredinnick, CEO of AJ Lucas Group Limited

A powerhouse within the energy industry, Brett Tredinnick is the CEO of Drilling Operations at AJ Lucas Group Limited.
Elementos (ASX:ELT) - Chairman, Andy Greig - The Market Herald

" Elementos (ASX:ELT) CEO Chris Creagh steps down

Elementos (ELT) CEO Chris Creagh has stepped down from his position as part of a board restructure.
LUCRF Super - CEO, Charlie Donnelly - The Market Herald

" Charlie Donnelly, CEO of LUCRF Super

Putting the workers first was already in the lifeblood of CEO Charlie Donnelly long before taking on the reigns at LUCRF Super.
RareX (ASX:REE) appoints John Young as Non-Executive Chairman

" RareX (ASX:REE) appoints John Young as Non-Executive Chairman

Following an extensive search, RareX (REE) has appointed Mr John Young to the Board as Non-Executive Chairman.